

Neuroscience Letters 260 (1999) 204-206

Neuroscience Letters

Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis

Hideo Tohqi*, Takashi Abe, Kinya Yamazaki, Takahiko Murata, Eri Ishizaki, Chiaki Isobe

Department of Neurology, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 020-8505 Japan

Received 30 October 1998; received in revised form 30 November 1998; accepted 30 November 1998

Abstract

To determine the role of free radical mechanisms in the pathogenesis of amyotrophic lateral sclerosis (ALS), cerebrospinal fluid concentrations of oxidized nitric oxide (NO) products (nitrite and nitrate) and reduced and oxidized forms of glutathione (GSH and GSSG, respectively) were compared between patients with the sporadic form of ALS (SALS) and controls. In the SALS patients, the nitrate levels were significantly higher (by 73%) in contrast to remarkably lower GSSG/GSH ratio, approximately 3-fold, compared to controls. These results suggest that NO production or oxidation is activated in SALS patients, leading to a decrease in superoxide radicals to oxidize GSH. The subsequent generation of a highly reactive anion, peroxynitrite, may play a causal role in the pathogenesis of SALS. © 1999 Elsevier Science Ireland Ltd. All rights reserved.

Keywords: Amyotrophic lateral sclerosis; Nitric oxide; Glutathione

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disease characterized by the selective degeneration of upper and lower motor neurons, leading to death usually within 5 years. Approximately 5-10% of ALS is familial (FALS) with the remaining 90-95% arising sporadically (SALS). Although still unknown, the pathogenesis of ALS is hypothesized to involve free radical injury [3], glutamatemediate excitotoxicity [10], or cytoskeletal abnormalities [7–9]. The recent discovery of point mutations and a small deletion in the Cu/Zn superoxide dismutase gene (SOD1) on chromosome 21 in some FALS and SALS [1,15,20,21,23] supports the free radical hypothesis for the pathogenesis of ALS. The enzymatic activity of SOD1 to scavenge superoxide radicals generally decreases upon genetic mutation. However, this activity is unaltered in some FALS patients [1,5] and even increases in transgenic mice [11]. In SALS, reduced [19,23] or normal [6] SOD1 activity and increased SOD1 mRNA levels [4] in the central nervous system (CNS) have been reported. Free radicals are reduced by scavengers such as glutathione (GSH) and α - tocopherol, which are themselves oxidized to the oxidized form of glutathione (GSSG) and α -tocopherol quinone, respectively. Free radical production is also linked to the excitotoxicity hypothesis [10]. In this model, stimulation of glutamate-mediated neurotransmission causes excessive Ca^{2+} influx and nitric oxide (NO) production, and resultant overproduced NO is oxidized to a highly reactive anion, peroxynitrite (ONOO $^-$), leading to neuronal damage [3]. Peroxynitrite is in turn metabolized to the more stable oxidation products nitrite (NO $^-$ 2) and nitrate (NO $^-$ 3). To investigate the role of free radicals in the pathogenesis SALS, we for the first time determined concentrations of oxidized NO products, NO $^-$ 2 and NO $^-$ 3, and reduced (GSH) and oxidized (GSSG) forms of glutathione, a free radical scavenger, in the cerebrospinal fluid (CSF) of SALS patients.

Throughout this study, SALS was diagnosed based on neurological history, neurological examination, and laboratory tests [17]. The severity of the disease was evaluated using the ALS index developed by Jablecki et al. [14], which is derived by adding disability scores in 12 areas, with a maximum score of 40. Controls were neurologically normal patients who underwent lumbar anesthesia for minor

^{*} Corresponding author. Fax: +81 19 6549860.

surgery. The SALS patients and controls used for analysis of NO_2/NO_3^- and GSH/GSSG were different. Nitrite and nitrate were determined in 18 SALS patients (60 \pm 13 years old) with a disease duration of 1.2 \pm 0.9 years and an ALS score of 13.9 \pm 4.5, and in 14 controls (62 \pm 11 years old). GSH and GSSG were determined in 12 SALS patients (61 \pm 8 years old) with a disease duration of 0.9 \pm 0.6 years and an ALS score of 11.7 \pm 5.4, and in 15 controls (68 \pm 5 years old). All patients were admitted to the hospital and were administered a standard diet. Informed consent was obtained from all patients. Lumbar CSF was obtained with the patients in the lateral decubitus position between 09:00 and 10:00 h after overnight bed-rest and fasting. The CSF samples drawn from the patients were rapidly frozen and stored at -80° C for 1 month to 2 years.

The nitrite and nitrate concentrations were determined according to Yamada and Nabeshima (1997) [24]. A 20 µl aliquot of each CSF sample was injected into an automated NO detector-HPLC system (ENO-10; Eicom, Kyoto, Japan). NO₂ and NO₃ were separated using a reversephase separation column (NO-PAK, 4.6×50 mm; Eicom, Kyoto, Japan), and NO₃ was reduced to NO₂ in a reduction column (NO-RED; Eicom, Kyoto, Japan). NO2 was mixed with Griess reagent to form a purple azo dye in a reaction coil. The separation and reduction columns and the reaction coil were maintained at 35°C. The product dye absorbance at 540 nm was measured using a flow-through spectrophotometer (NOD-10; Eicom, Kyoto, Japan). The mobile phase (10% methanol containing 0.15 M NaCl/NH₄Cl and 0.5 g/l 4 Na-EDTA) was delivered at a rate of 0.33 ml/min; the Griess reagent (1.25% HCl containing 5 g/l sulfanilamide with 0.25 g/l N-naphthylethylenediamine) was delivered at a rate of 0.1 ml/min. The detection limit of both NO₂ and NO₃ was 10 nM. NaNO₂ and NaNO₃ were obtained from Wako Pure Chemical Industries (Osaka, Japan).

Simultaneous determination of GSH and GSSG was performed as described previously by Harvey et al. [12]. Briefly, a 500-µl sample of the CSF was mixed with 500 μl of 0.6 N perchloric acid containing 1 mM EDTA, and centrifuged at 3000 rev./min for 10 min. A 500-µl aliquot of supernatant was stored at -80°C. A 100 μl aliquot of each sample was analyzed using an HPLC system (MCM C18 reversed phase column, 250×4.6 mm, MC medical, Tokyo, Japan) equipped with an electrochemical detector (Model 5,100 A, ESA, Bedford, MA, USA). The electrode potentials were maintained at 0.75 V for the guard cell, 0.4 V for the conditioning cell, 0.6 V for detector I (for GSH), and 0.7 V for detector II (for GSSG). The mobile phase consisted of 0.01 M sodium perchlorate monohydrate containing 0.15 mM sodium octanesulfonic acid (pH 2.7), and acetonitrile (98:2). The detection limit of both GSH and GSSG was 100 pM. GSH and GSSG were obtained from Sigma Chemical (St. Louis, MO, USA).

While nitrite levels were unaltered, nitrate levels were significantly higher in SALS patients (by 73%, P < 0.01) (Fig. 1A,B), suggesting overproduction of NO. The GSH

level was significantly higher (by 102%, P < 0.001), and the GSSG level was significantly lower (by 33%, P < 0.01) in the SALS patients than in the controls, with a significantly lower (3-fold) GSSG/GSH ratio in the SALS patients than controls (P < 0.001) (Fig. 1C,D).

The present results demonstrate a significant increase in the nitrate concentration and a remarkable reduction in the GSSG/GSH ratio in the CSF of SALS patients. The mechanisms by which NO production increases in SALS are unknown. Although the possibility that the increased nitrate levels may be in part accounted for by increased catabolism, they are most likely glutamate-mediated [3,10] in the context of currently proposed hypotheses for the pathogenesis of ALS. The findings on GSH and GSSG are very similar to those of our previous report in which the ratio of α -tocopherol quinone (α -TQ) to α -tocopherol (α -TOH) concentrations remarkably decreased in the CSF from patients with SALS [22]. The interpretation of these findings is somewhat difficult. However, superoxide reacts with NO to form the




Fig. 1. Typical chromatograms of cerebrospinal fluid samples for glutathione (GSH) and oxidized glutathione (GSSG) in (A) and nitrite and nitrate in (C). Concentrations of GSH and GSSG (B) and nitrite and nitrate (D) with means (columns) and standard errors (vertical bars) are compared between controls and patients with the sporadic form of amyotrophic lateral sclerosis (SALS). In (D), the left ordinate scales indicate concentrations, and the right ordinate scales indicate the ratio of GSSG/GSH. *P< 0.01, **P< 0.001 compared with controls using Mann–Whitney test.

powerful oxidant, peroxynitrite (ONOO⁻), 3-fold faster $(6.7 \times 10^9 \text{ M}^{-1}\text{s}^{-1})$ than SOD1 $(2 \times 10^9 \text{ M}^{-1}\text{s}^{-1})$ [13,16], and 10 000-fold faster than GSH $(6.7 \times 10^5 \text{ M}^{-1}\text{s}^{-1})$, α-TOH $(5 \times 10^5 \text{ M}^{-1}\text{s}^{-1})$, and ascorbic acid $(5-27 \times 10^4 \text{ M}^{-1}\text{s}^{-1})$ [2,18]. Moreover, NO $(\approx \mu\text{M})$ in the CSF is approximately 1000-times more abundant than either GSH or α-TOH $(\approx n\text{M})$. Therefore, one possibility may be that oxidation of overproduced NO may greatly surpass oxidation of GSH and α-TOH, which result in the reduction in the generation of GSSG and α-TQ.

In conclusion, the concentration of oxidative NO products is significantly higher and that of the oxidized form of a free radical scavenger GSSG is markedly lower in the CSF of SALS patients, suggesting activated NO production or oxidation. These findings support the hypothesis that glutamate-mediated overproduction of NO and subsequent generation of peroxynitrite play an important role in the pathogenesis of SALS.

We wish to thank Ms. Yoko Iwa for her technical assistance and Ms. Shiho Hinata for her secretarial assistance. This study was supported in part by the Ministry of Education and Culture and the Ministry of Health and Welfare, Japan.

- [1] Aoki, M., Abe, K., Houi, K., Ogasawara, M., Matsubara, Y., Kobayashi, T., Mochio, S., Narisawa, K. and Itoyama, Y., Variance of age at onset in a Japanese family with amyotrophic lateral sclerosis associated with a novel Cu/Zn superoxide dismutase mutation, Ann. Neurol., 37 (1995) 676–679.
- [2] Asada, K. and Kanematsu, S., Reactivity of thiols with superoxide radicals, Agr. Biol. Chem., 40 (1976) 1891–1892.
- [3] Beckman, J.S., Chen, J., Crow, J.P. and Ye, Y.Z. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration, Progress Brain Research, Vol. 103, 1994, pp. 371–380.
- [4] Bergeron, C., Muntasser, S., Somerville, M.J., Weyer, L. and Percy, M.E., Copper/zinc superoxide dismutase mRNA levels are increased in sporadic amyotrophic lateral sclerosis motorneurons, Brain Res., 659 (1994) 272–276.
- [5] Borchelt, D.R., Guarnieri, M., Wong, P.C., Lee, M.K., Slunt, H.S., Xu, Z.-S., Sisodia, S.S., Price, D.L. and Cleveland, D.W., Superoxide dismutase 1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function, J. Biol. Chem., 270 (1995) 3234–3238.
- [6] Bowling, A.C., Schulz, J.B., Brown, R.H. and Beal, M.F., Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis, J. Neurochem., 61 (1993) 2322–2325.
- [7] Collard, J.-F., Côté, F. and Julien, J.-P., Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis, Nature, 375 (1995) 61–64.
- [8] Côté, F., Collard, J.-F. and Julien, J.-P., Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis, Cell, 73 (1993) 35–46.
- [9] Figlewicz, D.A., Krizus, A., Martinoli, M.G., Meininger, V., Dib, M., Rouleau, G.A. and Julien, J.P., Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis, Hum. Mol. Genet., 3 (1994) 1757–1761.

- [10] Garthwaite, J., Glutamate, nitric oxide and cell-cell signalling in the nervous system, Trends Neurosci., 14 (1991) 75–82.
- [11] Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.M., Deng, H.-X., Chen, W., Zhai, P., Sufit, R.L. and Siddique, T., Motor neurodegeneration in mice that express a human Cu, Zn superoxide dismutase mutation, Science, 264 (1994) 1772–1775.
- [12] Harvey, P.R.C., Ilson, R.G. and Strasberg, S.M., The simultaneous determination of oxidized and reduced glutathiones in liver tissue by ion pairing reverse phase high performance liquid chromatography with a coulometric electrochemical detector, Clin. Chim. Acta, 180 (1989) 203–212.
- [13] Huie, R.E. and Padmaja, S., The reaction of NO with superoxide, Free Rad. Res. Commun., 18 (1993) 195–199.
- [14] Jablecki, C.K., Berry, C. and Leach, J., Survival prediction in amyotrophic lateral sclerosis, Muscle Nerve, 12 (1989) 833– 841
- [15] Jones, C.T., Swingler, R.J. and Brock, D.J.H., Identification of a novel SOD1 mutation in an apparently sporadic amyotrophic lateral sclerosis patients and the deletion of Ile 113 Thr in three others, Hum. Mol. Genet., 3 (1994) 649–650.
- [16] Klug, D., Rabani, J. and Fridovich, I., A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis, J. Biol. Chem., 247 (1972) 4839–4842.
- [17] Mulder, D.W., Motor neuron disease. In P.J. Dyck, P.K. Thomas, E.H. Lambert and R. Bunge (Eds.), Peripheral Neuropathy, Saunders, Philadelphia, PA, 1984, pp. 1525–1536.
- [18] Niki, E., Saito, T., Kawakami, A. and Kamiya, Y., Inhibition of oxidation of methyl linoleate in by vitamin E and vitamin C, J. Biol. Chem., 259 (1984) 4177–4182.
- [19] O'Reilly, S.A., Roedica, J., Nagy, D., Hallewell, R.A., Alderson, K., Marklund, S.L., Kuby, J. and Kushner, P.D., Motor neuronastrocyte interactions and levels of Cu, Zn superoxide dismutase in sporadic amyotrophic lateral sclerosis, Exp. Neurol., 131 (1995) 203–210.
- [20] Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J.P., Deng, H.X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S.M., Berger, R., Tanzi, R.E., Haperin, J.J., Herzfeldt, B., Van den Bergh, R., Hung, W.Y., Bird, T., Deng, G., Mulder, D.W., Smyth, C., Laing, N.G., Soriano, E., Pericack-Vance, M.A., Haines, J., Rouleau, G.A., Gusella, J.S., Horvitz, H.R. and Brown, R.H. Jr., Mutations in Cu/Zu superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature, 362 (1993) 59–62.
- [21] Siddique, T., Figlewicz, D.A., Pericak-Vance, M.A., Haines, J.L., Rouleau, G., Jeffers, A.J., Sapp, P., Hung, W.-Y., Bebout, J., McKenna-Yasek, D., Deng, G., Horvitz, H.R., Gusella, J.F., Brown, R.H. Jr. and Roses, A.D., Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic locus heterogeneity, N. Engl. J. Med., 324 (1991) 1381–1384.
- [22] Tohgi, H., Abe, T., Saheki, M., Yamazaki, K. and Takahashi, S., α-Tocopherol quinone level is remarkably low in the cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis, Neurosci. Lett., 207 (1996) 5–8.
- [23] Uchino, M., Ando, Y., Tanaka, Y., Nakamura, T., Uyama, E., Mita, S., Murakami, T. and Ando, M., Decrease in Cu/Zn- and Mn-superoxide dismutase activities in brain and spinal cord of patients with amyotrophic lateral sclerosis, J. Neurol. Sci., 127 (1994) 61–67.
- [24] Yamada, K. and Nabeshima, T., Simultaneous measurement of nitrite and nitrate levels as indices of nitric oxide release in the cerebellum of conscious rats, J. Neurochem., 68 (1997) 1234– 1243.